Literature DB >> 24502302

The clinical significance of drug interactions between dermatological and psychoactive medications.

John W Frew1.   

Abstract

Dermatological disease is commonly associated with psychological morbidity because of its visible nature. The burden of living with a chronic dermatological illness can contribute to the development of psychiatric illness and conversely, such conditions can result in the exacerbation of preexisting dermatological disease. It may also reduce a patient's compliance to treatment, result in loss to follow-up and a decreased level of functioning and quality of life. In dermatological patients who suffer from psychiatric symptoms, medical management used in their treatment may have significant interactions with systemic medications used to treat their dermatological condition. A well-known example of this is lithium's ability to exacerbate psoriasis. Such interactions can result in suboptimal treatment of their psychiatric and/or dermatological condition. The present paper aimed to review the literature for documented interactions and the level of clinical significance between dermatological and psychoactive medications. Such information is clinically relevant to the practicing dermatologist in order to minimize adverse effects and drug-drug interactions in dermatological patients.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  adverse effects; drug interactions; psychoactive medications

Mesh:

Substances:

Year:  2014        PMID: 24502302     DOI: 10.1111/dth.12003

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  2 in total

Review 1.  Psoriasis and Atopic Dermatitis.

Authors:  Christopher E M Griffiths; Peter van de Kerkhof; Magdalena Czarnecka-Operacz
Journal:  Dermatol Ther (Heidelb)       Date:  2017-02-01

2.  Important drug classes associated with potential drug-drug interactions in critically ill patients: highlights for cardiothoracic intensivists.

Authors:  Shadi Baniasadi; Behrooz Farzanegan; Maryam Alehashem
Journal:  Ann Intensive Care       Date:  2015-11-24       Impact factor: 6.925

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.